CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 12 enrolled
Drug / intervention
Cocaine +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05019430
NCT05019430Early Ph 1Completed

Behavioral Effects of Drugs (Inpatient): 42 (Cocaine and Zolmitriptan)

William Stoops·interventional·Posted Aug 24, 2021·Updated Aug 5, 2025

In Brief

A Early Phase 1 clinical trial evaluating Cocaine, Placebo oral capsule, and 1 other intervention for Cocaine Use Disorder. Completed, enrolled 12 participants across 1 site.

Detailed Summary

Cocaine potently inhibits the reuptake of serotonin (5-HT). Increased synaptic 5-HT resulting from this reuptake inhibition activates multiple 5-HT receptor subtypes. Some of these receptor subtypes have been implicated in the abuse-related effects of cocaine, including its primary reinforcing effects (i.e., cocaine taking behavior). 5-HT1b receptors, which are autoreceptors on 5-HT nerve endings that regulate 5-HT release and heteroreceptors that also mediate other neurotransmitter release, play a particularly important role in cocaine effects, likely because they are highly expressed in the mesocorticolimbic system. The 5-HT1b system displays profound dysregulation during both active cocaine use and abstinence. Initial preclinical research showed that selective 5-HT1b agonists enhanced the reinforcing and locomotor effects of cocaine during ongoing cocaine administration, but subsequent research showed that these agents robustly attenuated reinstatement of cocaine- and cue-primed cocaine seeking behavior. These findings have been replicated in rigorously conducted studies using multiple schedules of reinforcement and negative sucrose reinforcement controls across laboratories. Notably, though, these preclinical studies used compounds not approved for use in humans, hindering translation. Recently published data show that zolmitriptan, a commercially available selective 5-HT1b agonist migraine medication, also selectively attenuates the reinforcing and other abuse-related effects of cocaine, regardless of stage of use (i.e., ongoing or extinguished cocaine self-administration). Although a robust preclinical literature supports the premise that 5-HT1b activation reduces a number of cocaine-associated behaviors (e.g., self-administration, cocaine seeking), this area remains unstudied in humans. The overarching goal of this project is to advance these promising preclinical findings, specifically those with zolmitriptan, to a clinical population, thereby demonstrating that the 5-HT1b system plays a key role in the effects of cocaine in humans

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Early Ph 1CompletedFinished
20222023202420252026
First PostedAug 24, 2021
Enrollment StartOct 15, 2021
Primary CompletionJan 9, 2025
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 4.9 years ago

Interventions

Cocainedrug

The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and zolmitriptan.

Placebo oral capsuledrug

The pharmacodynamic effects of placebo will be determined.

Zolmitriptandrug

The pharmacodynamic effects of zolmitriptan maintenance will be determined.